Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BTCY 
Biotricity Inc (BTCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BTCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.39% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.21M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 36314 | Beta 1.19 | 52 Weeks Range 0.19 - 1.60 | Updated Date 03/30/2025 |
52 Weeks Range 0.19 - 1.60 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -97.04% | Operating Margin (TTM) -9.42% |
Management Effectiveness
Return on Assets (TTM) -59.33% | Return on Equity (TTM) -4100.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36556021 | Price to Sales(TTM) 0.71 |
Enterprise Value 36556021 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA -3.76 | Shares Outstanding 24394400 | Shares Floating 16908652 |
Shares Outstanding 24394400 | Shares Floating 16908652 | ||
Percent Insiders 40.89 | Percent Institutions 0.39 |
Analyst Ratings
Rating 3 | Target Price 4 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biotricity Inc
Company Overview
History and Background
Biotricity Inc., founded in 2013, focuses on developing and marketing medical-grade wearable bio-sensors for remote patient monitoring. It aims to reduce healthcare costs and improve patient outcomes through early detection and preventative care.
Core Business Areas
- Remote Patient Monitoring (RPM): Development and provision of wearable biosensors and software platform for remote monitoring of vital signs and physiological data.
Leadership and Structure
Dr. Waqaas Al-Siddiq is the CEO and Founder. The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Bioflux: A wearable ECG (electrocardiogram) device used for continuous cardiac monitoring. It captures real-time heart activity data and transmits it securely to healthcare providers. Competitors include iRhythm Technologies (IRTC) and AliveCor. Biotricity does not publicly release market share data.
- Biotres: A 3-lead ECG device. Competitors include iRhythm Technologies (IRTC) and AliveCor. Biotricity does not publicly release market share data.
Market Dynamics
Industry Overview
The remote patient monitoring market is experiencing rapid growth driven by aging populations, increasing chronic disease prevalence, and technological advancements in wearable sensors and data analytics.
Positioning
Biotricity positions itself as a provider of comprehensive, medical-grade RPM solutions focused on cardiac monitoring.
Total Addressable Market (TAM)
The global remote patient monitoring market is estimated at over $50 billion. Biotricity's TAM is within the cardiac monitoring segment of the RPM market, but they do not have a significant market presence.
Upturn SWOT Analysis
Strengths
- Proprietary wearable sensor technology
- Focus on medical-grade accuracy and reliability
- Potential for recurring revenue through subscription-based monitoring services
Weaknesses
- Limited market share
- Negative Revenue and Net Income
- High operating expenses
- Reliance on external manufacturing partners
- Limited Brand awareness
- Limited Funding/capital
Opportunities
- Expanding into new therapeutic areas (e.g., respiratory monitoring)
- Partnerships with hospitals, clinics, and insurance companies
- Geographic expansion into international markets
- Growing adoption of telemedicine and remote healthcare services
- Further product development based on technological advancement
Threats
- Intense competition from established medical device companies
- Evolving regulatory landscape for remote patient monitoring
- Reimbursement challenges from healthcare payers
- Technological obsolescence
- Economic Downturn
Competitors and Market Share
Key Competitors
- IRTC
- ALGN
Competitive Landscape
Biotricity faces significant competition from larger, more established players in the remote patient monitoring market. Its competitive advantage lies in its proprietary technology, but it needs to improve its market penetration and financial stability.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth has been inconsistent and limited.
Future Projections: Future growth projections are difficult to ascertain due to the company's volatile financial performance and market position.
Recent Initiatives: Biotricity has been focused on securing FDA approvals and expanding its product offerings.
Summary
Biotricity is a small company in a competitive market. The company has novel technology but has been unable to translate it into profits. Biotricity has been unable to gain market share. It faces threats from competitors as well as funding issues that will impact its ability to grow.
Similar Companies
ALGN
Align Technology Inc
ALGN
Align Technology Inc
IRTC
iRhythm Technologies Inc
IRTC
iRhythm Technologies Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biotricity Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2016-02-18 | Founder, President, CEO & Chairman Dr. Waqaas Al-Siddiq Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 55 | Website https://www.biotricity.com |
Full time employees 55 | Website https://www.biotricity.com | ||
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity, Inc. is based in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.